JASON BREEN
Goodwin Proctor
Jason Breen is a Los Angeles based partner in Goodwin’s Technology Companies & Life Sciences group. He represents start-up and later-stage companies in the software, technology and life sciences industries throughout their corporate life cycle, with a particular focus on mergers, acquisitions, divestitures, joint ventures, financings and other strategic transactions. He also represents venture capital, growth equity and private equity funds focusing on technology and life sciences companies.
Known for his leadership and wide breadth of experience, Breen has been one of the lead partners on several noteworthy deals, including: advising BridgeBio Pharma, a Palo Alto-based company that finds, develops, and delivers breakthrough medicines for genetic diseases, on its 2018 financing of approximately $299 million. He also advised on its sale of 20.5 million shares priced at $17. Raising $348.5 million, BridgeBio has been noted as the largest biotech IPO of 2019 to date.
Breen advised BlueRock Therapeutics, a leading engineered stem cell therapy company, on its agreement to be fully acquired by Bayer AG. With Bayer currently holding 40.8 percent stake, the investment corresponds to a total company value of BlueRock Therapeutics of approximately $1 billion. Breen also advised Century Therapeutics, Inc. in its launch with $250 million in financing from Bayer, Versant Ventures and Fujifilm Cellular Dynamics Inc. The proceeds will enable Century to advance to multiple programs into the clinic for hematologic and solid malignancies. He also advised Arvinas, Inc. on an agreement with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
